Tandem 2024 Reflections: S-OA-F - Oral Abstract - Session F - Lymphoma and Myeloma

What stood out to you as the most crucial points discussed at S-OA-F - Oral Abstract - Session F - Lymphoma and Myeloma? 

At oral session OA-F about plasma cell disorders, updated data from the CARTITUDE-2 trial of cilta-cel CAR-T in multiple myeloma were presented.

What stood out the most were the findings from CARTITUDE-2 cohort B, namely patients with “functional high-risk myeloma” with relapse within 1 year of therapy (including ASCT, if occurs). These patients have historically had a terrible prognosis, and here - after a “one and done” CAR-T infusion - their 2-year PFS was 73%! 

While further studies are needed with both ide-cel and cilta-cel, as well as with newer products in myeloma, this suggests that CAR-T may be the answer we’re looking for in terms of treating our patients with functional high-risk myeloma.